FIG. 1



Untransfectant
Full ICAM-1
Control
MD-2
Control
R6-5-D6
Control
MD-2
Control
R6-5-D6

FIG. 2



Untransfectant
2nd Ab only
Human ICAM-1
MD-2
R6-5-D6
Murine ICAM-1
MD-2
R6-5-D6
h1m2345 ICAM-1
MD-2
R6-5-D6
h12m345 ICAM-1
MD-2
R6-5-D6
50
0
10^0
10^1
10^2
10^3
10^4

FIG. 3




FIG. 4



Control
R6-5-D6 10 μg
R6-5-D6 1 μg
R6-5-D6 0.1 μg
MD-2 10 μg
MD-2 1 μg
MD-2 0.1 μg
80
0
10^0 10^1 10^2 10^3 10^4

FIG. 5




A
MFI
1000
800
600
400
300
200
100
0
Control
R6-5-D6
MD-2
Control+LPS
R6-5-D6+LPS
MD-2+LPS
MHC I
MHC II
CD80
CD86
CD40
CD83
B
Conc. (pg/ml)
10^5
10^4
10^3
10^2
10^1
10^0
10^{-1}
IL-6
IL-10
IL-12p70
IFN-γ
TNF-α

FIG. 6

A


% of human CD45+ cells
80
70
60
50
40
30
20
10
0
4
5
7
9
11
13
16
Weeks after human cell transfer

B



% of CD3+ cells in Human CD45+ cells
10.0
7.5
5.0
2.5
0.0
2wk
5wk
7wk
9wk
11wk
13wk
16wk
weeks after human cell transfer

FIG. 7



Control antibody
Blood glucose (mg/dl)
600
500
400
300
200
100
0
0 10 20 30 40 50 60 70 80 90
Days after rat islet graft
MD-2
Blood glucose (mg/dl)
600
500
400
300
200
100
0
0 10 20 30 40 50 60 70 80 90
Days after rat islet graft

FIG. 8

